Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 6/20 | 0.56 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.56 |
| ▸ | MPO | P05164 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1971111 | 0.86 | HTR2A (0.76) | GPR84SLC6A4HTR2ATRPM8MPO | |
| SCHEMBL892446 | 0.85 | HTR2A (0.75) | GPR84SLC6A4HTR2ATRPM8MPO | |
| SCHEMBL27929621 | 0.85 | GPR84 (1.00) | GPR84SLC6A4HTR2ATRPM8ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2537521 | 0.84 | HTR2A (0.73) | GPR84SLC6A4HTR2ATRPM8MPO | |
| Hydrochloric Acid SCHEMBL30396693 | 0.84 | HTR2A (0.73) | GPR84SLC6A4HTR2ATRPM8MPO | |
| SCHEMBL3195765 | 0.81 | GPR84 (0.73) | GPR84SLC6A4HTR2ATRPM8ALDH1A1 | |
| SCHEMBL2404863 | 0.81 | GPR84 (0.73) | GPR84SLC6A4HTR2ATRPM8HTR2C | |
| SCHEMBL4185239 | 0.79 | HTR2A (0.53) | GPR84HTR2ATRPM8MPOHTR2C | |
| SCHEMBL24452687 | 0.79 | GPR84 (0.69) | GPR84SLC6A4HTR2ATRPM8HTR2C | |
| SCHEMBL7716375 | 0.79 | GPR84 (0.69) | GPR84SLC6A4HTR2ATRPM8HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3089746-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | Lifesci Pharmaceuticals, Inc. (BB) | 2016-11-09 | — | — | EP | disclosed |
| WO-2015103317-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015103317-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2015-07-09 | — | — | WO | disclosed |
| US-7705034-B2 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-04-27 | — | — | US | disclosed |
| CN-101522615-A | Vinylogous acids derivatives as chymase inhibitors | HOFFMANN LA ROCHE (CH) | 2009-09-02 | — | — | CN | disclosed |
| EP-2074090-A1 | VINYLOGOUS ACIDS DERIVATIVES AS CHYMASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-20080096953-A1 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. | 2008-04-24 | — | — | US | disclosed |
| WO-2008043698-A1 | VINYLOGOUS ACIDS DERIVATIVES AS CHYMASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096953-A1 | Vinylogous acid derivatives | CMA1, TPSG1, GAA | GPR84 686/4885SLC6A4 3257/4885HTR2A 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.